Result:Steady· Market: Flat
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 16.39 | 2.8% | 1.9% |
| Total Income | 16.41 | 4.7% | 1.9% |
| Expenditure | 16.05 | 2.6% | 2.0% |
| PBT | 0.36 | 51.8% | 6.4% |
| Net Profit | 0.23 | 425.8% | 2.2% |
| OPM | 3.27% | 0.13pp | 0.13pp |
| NPM | 1.39% | 1.14pp | 0.05pp |
| EPS | 0.37 | 825.0% | 60.9% |
Revenue declined 1.9% YoY with only marginal PAT growth (2.2%) off a negligible base, keeping this an in-line, unremarkable quarter for the pharma business.
Informational and educational content only. Not investment advice.